Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

SLDB

Solid Biosciences Inc

Feb 21 • 04:00PM ET

5.78

Dollar change -0.22
Percentage change -3.67	%

Healthcare • Biotechnology • USA • NASD

Peers: SRPT PFE BMRN BLUE QURE EDIT RGEN NTLA ABEO VYGR

| Held by: IWM VTI IWN IBB VXF FESM VTWO IWC DFAT AVSC

Index	RUT	P/E	-	EPS (ttm)	-3.04	Insider Own	20.66%	Shs Outstand	76.32M	Perf Week	46.70%
Market Cap	441.12M	Forward P/E	-	EPS next Y	-2.66	Insider Trans	64.63%	Shs Float	60.55M	Perf Month	85.26%
Income	-102.44M	PEG	-	EPS next Q	-0.80	Inst Own	40.76%	Short Float	4.38%	Perf Quarter	15.60%
Sales	0.00M	P/S	-	EPS this Y	39.19%	Inst Trans	2.11%	Short Ratio	1.29	Perf Half Y	-38.05%
Book/sh	4.29	P/B	1.35	EPS next Y	9.57%	ROA	-51.66%	Short Interest	2.65M	Perf Year	-42.77%
Cash/sh	2.24	P/C	2.58	EPS next 5Y	18.10%	ROE	-65.79%	52W Range	2.88 - 15.05	Perf YTD	44.50%
Dividend Est.	-	P/FCF	-	EPS past 5Y	32.21%	ROI	-54.21%	52W High	-61.59%	Beta	2.12
Dividend TTM	-	Quick Ratio	7.85	Sales past 5Y	-35.14%	Gross Margin	-	52W Low	100.69%	ATR (14)	0.65
Dividend Ex-Date	-	Current Ratio	7.85	EPS Y/Y TTM	34.13%	Oper. Margin	-	RSI (14)	69.94	Volatility	21.73% 12.76%
Employees	88	Debt/Eq	0.15	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.08	Target Price	17.20
Option/Short	Yes / Yes	LT Debt/Eq	0.13	EPS Q/Q	24.51%	Payout	-	Rel Volume	1.05	Prev Close	6.00
Sales Surprise	-	EPS Surprise	-18.23%	Sales Q/Q	-	Earnings	Nov 06 AMC	Avg Volume	2.06M	Price	5.78
SMA20	51.13%	SMA50	46.94%	SMA200	-11.34%	Trades		Volume	2,159,869	Change	-3.67%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-08-25	Initiated	Truist	Buy	$16
Dec-13-24	Initiated	Wedbush	Outperform	$16
Dec-10-24	Initiated	JMP Securities	Mkt Outperform	$15
Jul-15-24	Upgrade	JP Morgan	Neutral → Overweight	$10 → $15
Jun-24-24	Upgrade	Leerink Partners	Market Perform → Outperform	$12
May-31-24	Resumed	Piper Sandler	Overweight	$20
Mar-28-24	Initiated	William Blair	Outperform	$40
Mar-15-24	Initiated	Citigroup	Buy	$16
Mar-14-24	Upgrade	Piper Sandler	Neutral → Overweight	$8 → $20
Dec-08-23	Initiated	H.C. Wainwright	Buy	$9
Jul-12-21	Initiated	Piper Sandler	Neutral	$6
May-27-21	Initiated	Jefferies	Buy	$7
Mar-16-21	Upgrade	SVB Leerink	Mkt Perform → Outperform	$3 → $15
Mar-09-21	Initiated	Barclays	Overweight	$13
Jan-08-21	Upgrade	Credit Suisse	Underperform → Neutral	$2 → $7
Jul-28-20	Downgrade	SVB Leerink	Outperform → Mkt Perform
May-07-20	Downgrade	Evercore ISI	Outperform → In-line
Oct-11-19	Initiated	Evercore ISI	Outperform	$22
Aug-29-19	Downgrade	Citigroup	Neutral → Sell	$6
Aug-19-19	Upgrade	SVB Leerink	Mkt Perform → Outperform	$8 → $15

Show Previous Ratings

Feb-19-25 08:02AM	Solid Biosciences stock soars on early success in DMD gene therapy trial (Clinical Trials Arena) +22.08%
Feb-18-25 07:00AM	Solid Biosciences Announces Pricing of Underwritten Offering (GlobeNewswire) +31.51%
06:45AM	Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003 (GlobeNewswire)
06:36AM	Solid says early data suggest differentiated Duchenne gene therapy (BioPharma Dive)
Feb-09-25 06:12AM	Analysts Predict Up to ~450% Surge for These 2 Strong Buy Penny Stocks (TipRanks)
08:00AM	Loading…
Feb-04-25 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-21-25 08:30AM	Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia (GlobeNewswire)
Jan-15-25 04:05PM	Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines (GlobeNewswire)
Jan-08-25 04:05PM	Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -8.68%
Jan-07-25 04:15PM	Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich's Ataxia (GlobeNewswire)
Jan-06-25 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-23-24 04:05PM	Solid Biosciences Added to the Nasdaq Biotechnology Index (GlobeNewswire)
Dec-13-24 01:52PM	Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst (Benzinga)
Dec-04-24 08:05AM	Solid Biosciences reports inducement grant under Nasdaq listing rule (TipRanks)
08:00AM	Solid Biosciences Announces Collaboration with Mayo Clinic to Accelerate Gene Therapy Innovation and Advance Development of Cardiac Gene Therapies (GlobeNewswire)
08:00AM	Loading…
Dec-03-24 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -10.54%
Nov-26-24 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire)
Nov-14-24 08:00AM	Solid Biosciences to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-06-24 04:05PM	Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -6.03%
Nov-04-24 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-31-24 08:00AM	Solid Biosciences to Participate at the Truist Securities BioPharma Symposium (GlobeNewswire)
Oct-02-24 04:15PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-23-24 08:00AM	Solid Biosciences to Participate at Chardan's 8th Annual Genetic Medicines Conference (GlobeNewswire)
Sep-12-24 08:00AM	Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-04-24 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire)
Aug-13-24 04:08PM	Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) +14.54%
Aug-05-24 08:00AM	Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-01-24 04:19PM	Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.58%
08:00AM	Solid Biosciences Joins the Russell 3000 Index (GlobeNewswire)
07:52AM	Loading…
Jun-21-24 07:52AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
Jun-04-24 04:00PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-20-24 06:00AM	3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off (InvestorPlace)
May-15-24 12:53PM	SLDB Stock Earnings: Solid Biosciences Meets EPS for Q1 2024 (InvestorPlace)
07:52AM	Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results (GlobeNewswire)
May-07-24 07:00AM	Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire)
May-02-24 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.23%
Apr-03-24 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-02-24 10:35AM	Solid Biosciences (SLDB) Falls Despite FDA Rare Tag for DMD Drug (Zacks)
07:20AM	Solid Biosciences' SGT-003 receives rare pediatric disease designation (Pharmaceutical Business Review)
Apr-01-24 07:45AM	Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003 (GlobeNewswire) -6.61%
Mar-28-24 04:08PM	How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A Comeback (Investor's Business Daily) -6.53%
Mar-27-24 07:00AM	Solid Biosciences to Participate at Cantor's Virtual Muscular Dystrophy Symposium (GlobeNewswire) +5.01%
Mar-13-24 07:44AM	Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results (GlobeNewswire) +7.28%
Mar-07-24 07:00AM	Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD (GlobeNewswire) +7.86%
Mar-06-24 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire)
Feb-29-24 03:02AM	14 Stocks With Heavy Insider Buying In 2024 (Insider Monkey)
Jan-17-24 11:27AM	Solid Biosciences' (SLDB) DMD Drug Gets Orphan Tag, Stock Up (Zacks)
Jan-16-24 01:10PM	Hedge Fund and Insider Trading News: Anthony Scaramucci, Bill Ackman, Rokos Capital Management, ExodusPoint Capital, Alden Global Capital, Solid Biosciences Inc. (SLDB), and More (Insider Monkey)
08:00AM	Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003 (GlobeNewswire)
Jan-15-24 10:18AM	Solid Biosciences (SLDB) Rises 271% in 3 Months: Here's Why (Zacks)
Jan-08-24 07:09AM	Solid Biosciences Announces $109 Million Private Placement (GlobeNewswire) +7.59%
Jan-04-24 08:00AM	Solid Biosciences to Participate at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-08-23 05:37AM	Solid Biosciences' (SLDB) DMD Drug Gets Fast Track Tag, Stock Up (Zacks) -12.15%
Dec-07-23 08:00AM	Solid Biosciences Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Gene Therapy SGT-003 (GlobeNewswire) +68.42%
Nov-22-23 08:00AM	Solid Biosciences to Participate at 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire) +9.17%
Nov-16-23 08:29AM	Solid Biosciences (SLDB) Stock Up as FDA Clears DMD Drug IND (Zacks)
Nov-14-23 04:05PM	Solid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003 (GlobeNewswire) +27.93%
Nov-09-23 08:00AM	Solid Biosciences to Participate at Jefferies London Healthcare Conference (GlobeNewswire) -23.66%
Nov-08-23 04:17PM	Solid Biosciences Provides Third Quarter Business Update and Financial Results (GlobeNewswire)
Oct-02-23 08:00AM	Solid Biosciences Appoints Gabriel Brooks, M.D., as Chief Medical Officer (GlobeNewswire)
Sep-20-23 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire)
Sep-05-23 08:56AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire)
Aug-31-23 08:00AM	Solid Biosciences to Participate in Citis 18th Annual BioPharma Conference (GlobeNewswire)
Aug-14-23 04:17PM	Solid Biosciences Provides Second Quarter Business Update and Financial Results (GlobeNewswire)
Jun-01-23 08:00AM	Solid Biosciences to Participate at the Jefferies Healthcare Conference (GlobeNewswire)
May-22-23 08:00AM	Solid Biosciences to Participate at the Barclays Gene Editing & Therapy Summit (GlobeNewswire)
May-16-23 08:00AM	Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire)
May-11-23 09:35AM	Solid Biosciences Inc. (SLDB) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:30AM	Solid Biosciences Provides First Quarter Business Update and Financial Results (GlobeNewswire)
May-08-23 04:05PM	Solid Biosciences to Present at JMP Securities Life Sciences Conference (GlobeNewswire) +9.80%
Apr-21-23 08:00AM	Solid Biosciences to Participate in Chardans 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit (GlobeNewswire)
Apr-20-23 10:03AM	Will Alnylam Pharmaceuticals (ALNY) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-19-23 10:01AM	Will Solid Biosciences Inc. (SLDB) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-13-23 08:00AM	Solid Biosciences to Present at the 22nd Annual Needham Healthcare Conference (GlobeNewswire)
Mar-25-23 09:44AM	Solid Biosciences Full Year 2022 Earnings: EPS Misses Expectations (Simply Wall St.)
Mar-23-23 08:00AM	Solid Biosciences Provides Fourth Quarter and Full-Year 2022 Business Update and Financial Results (GlobeNewswire)
Mar-21-23 08:00AM	Solid Biosciences to Participate at BMO Biopharma Spotlight Series: Genetic Medicine Delivery (GlobeNewswire)
Mar-07-23 08:00AM	Solid Biosciences to Present at Barclays Global Healthcare Conference (GlobeNewswire) +5.01%
Mar-02-23 07:52AM	Solid Biosciences Inc.'s (NASDAQ:SLDB) 14% loss last week hit both individual investors who own 51% as well as institutions (Simply Wall St.)
Feb-08-23 08:00AM	Solid Biosciences to Present at SVB Securities Global Biopharma Conference (GlobeNewswire) -5.67%
Jan-26-23 08:00AM	Pathway Development Consortium Announces Publication in Human Gene Therapy on the Application of FDAs Accelerated Approval Pathway for AAV Gene Therapies for Patients with Duchenne Muscular Dystrophy (GlobeNewswire)
Jan-11-23 08:00AM	Solid Biosciences and Phlox Therapeutics Announce Strategic Research Collaboration Focused on Accelerating the Development of New Therapies for Rare Cardiac Diseases (GlobeNewswire) +5.04%
Jan-10-23 08:00AM	Solid Biosciences Outlines Strategy for Leadership in Precision Genetic Medicines with Focus on Neuromuscular and Cardiac Diseases (GlobeNewswire)
Jan-09-23 04:26PM	Solid Biosciences Reports Inducement Grant to Chief Financial Officer and Treasurer (GlobeNewswire)
08:01AM	Solid Biosciences Appoints Kevin Tan, CFA, as Chief Financial Officer (GlobeNewswire)
08:00AM	Solid Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-05-22 04:35PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:30AM	Solid Biosciences Announces Closing of Acquisition of AavantiBio and Concurrent $75 Million Private Placement (GlobeNewswire)
Dec-01-22 04:15PM	Solid Biosciences Announces Stockholder Approval of Acquisition of AavantiBio (GlobeNewswire)
Nov-22-22 08:00AM	Solid Biosciences to Participate at the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire)
Nov-10-22 08:55AM	Solid Biosciences Inc. (SLDB) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:34AM	Solid Biosciences Provides Third Quarter 2022 Business Update and Financial Results (GlobeNewswire)
Nov-08-22 06:25PM	Adicet Bio, Inc. (ACET) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-01-22 07:55AM	Techne (TECH) Lags Q1 Earnings and Revenue Estimates (Zacks)
Oct-27-22 10:02AM	Analysts Estimate Albireo Pharma (ALBO) to Report a Decline in Earnings: What to Look Out for (Zacks)
08:00AM	Solid Biosciences Announces a 1-for-15 Reverse Stock Split (GlobeNewswire)
Oct-26-22 10:02AM	Earnings Preview: Solid Biosciences Inc. (SLDB) Q3 Earnings Expected to Decline (Zacks)
Oct-20-22 02:41PM	7 Sizzling Stocks That Are Oblivious to the Manic Market (InvestorPlace)
Oct-17-22 11:30AM	Solid Biosciences Touts Encouraging Preclinical Data From Potential Duchenne Gene Therapy (Benzinga)

Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. It also focuses on developing treatments for neuromuscular and cardiac diseases. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bain Capital Life Sciences Inv	10% Owner	Feb 19 '25	Buy	4.03	1,000,000	4,030,000	5,034,582	Feb 21 05:48 PM
PERCEPTIVE ADVISORS LLC	Director	Feb 19 '25	Buy	4.03	5,000,000	20,150,000	11,833,539	Feb 21 04:17 PM
Adage Capital Management, L.P.	10% Owner	Feb 18 '25	Buy	7.56	252,545	1,909,240	4,248,084	Feb 19 04:16 PM
Hanrahan Jessie	Chief Regulatory Officer	Feb 14 '25	Sale	3.96	3,079	12,193	19,281	Feb 18 04:05 PM
Brooks Gabriel	Chief Medical Officer	Feb 14 '25	Sale	3.96	3,256	12,894	22,812	Feb 18 04:05 PM
Tan Kevin	CFO & Treasurer	Feb 14 '25	Sale	3.96	3,164	12,529	32,250	Feb 18 04:05 PM
Howton David T	Chief Operating Officer	Feb 14 '25	Sale	3.96	5,561	22,022	24,789	Feb 18 04:05 PM
Herzich Paul	Chief Technology Officer	Feb 14 '25	Sale	3.96	2,688	10,644	18,388	Feb 18 04:05 PM
Cumbo Alexander	President and CEO	Feb 14 '25	Sale	3.96	11,365	45,005	60,717	Feb 18 04:05 PM
Ganot Ilan	Director	Feb 14 '25	Sale	3.96	1,711	6,776	14,839	Feb 18 04:05 PM
Howton David T	Officer	Feb 14 '25	Proposed Sale	3.96	5,561	22,022		Feb 14 05:25 PM
Herzich Paul	Officer	Feb 14 '25	Proposed Sale	3.96	2,688	10,644		Feb 14 05:25 PM
Tan Kevin	Officer	Feb 14 '25	Proposed Sale	3.96	3,164	12,529		Feb 14 05:23 PM
Cumbo Alexander	Officer	Feb 14 '25	Proposed Sale	3.96	11,365	45,005		Feb 14 05:23 PM
Hanrahan Jessie	Officer	Feb 14 '25	Proposed Sale	3.96	3,079	12,193		Feb 14 05:20 PM
Ganot Ilan	Director	Jan 28 '25	Sale	3.11	144	448	11,689	Jan 29 06:14 PM
Tan Kevin	CFO & Treasurer	Jan 10 '25	Sale	3.89	4,073	15,849	24,789	Jan 13 06:51 PM
Ganot Ilan	Director	Jan 06 '25	Sale	4.31	1,056	4,551	11,445	Jan 07 05:29 PM
Hanrahan Jessie	Chief Regulatory Officer	Dec 03 '24	Sale	5.60	4,610	25,822	14,235	Dec 04 05:34 PM
Howton David T	Officer	Dec 03 '24	Proposed Sale	5.60	5,072	28,396		Dec 04 05:33 PM
Cumbo Alexander	President and CEO	Dec 03 '24	Sale	5.60	11,114	62,236	38,484	Dec 04 05:27 PM
Howton David T	Chief Operating Officer	Dec 03 '24	Sale	5.60	5,072	28,396	15,663	Dec 04 05:04 PM
Herzich Paul	Chief Technology Officer	Dec 03 '24	Sale	5.60	2,777	15,551	12,182	Dec 04 04:42 PM
Cumbo Alexander	Officer	Dec 03 '24	Proposed Sale	5.79	10,687	61,878		Dec 03 05:35 PM
Brooks Gabriel	Chief Medical Officer	Oct 21 '24	Sale	6.50	2,923	19,000	10,979	Oct 22 04:05 PM
Kahn Clare	Director	Jun 07 '24	Buy	7.67	1,100	8,442	1,100	Jun 11 02:15 PM
Ganot Ilan	Director	May 02 '24	Sale	10.33	462	4,772	9,507	May 06 06:48 PM

Dollar change -0.09
Percentage change -1.77	%

OLMA Olema Pharmaceuticals Inc daily Stock Chart

Peers: AMGN GILD VRTX REGN BIIB ONC INCY NBIX EXEL ACAD

| Held by: VTI IWM XBI VXF IBB IWN VTWO SCHA DFAS VHT

Index	RUT	P/E	-	EPS (ttm)	-2.19	Insider Own	20.06%	Shs Outstand	57.29M	Perf Week	3.31%
Market Cap	340.98M	Forward P/E	-	EPS next Y	-2.65	Insider Trans	-4.30%	Shs Float	54.62M	Perf Month	-12.15%
Income	-122.68M	PEG	-	EPS next Q	-0.64	Inst Own	84.44%	Short Float	15.40%	Perf Quarter	-42.18%
Sales	0.00M	P/S	-	EPS this Y	-7.49%	Inst Trans	13.19%	Short Ratio	7.39	Perf Half Y	-59.33%
Book/sh	3.47	P/B	1.44	EPS next Y	-15.38%	ROA	-46.92%	Short Interest	8.41M	Perf Year	-65.20%
Cash/sh	3.14	P/C	1.59	EPS next 5Y	-13.34%	ROE	-51.76%	52W Range	4.60 - 16.62	Perf YTD	-14.41%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-105.28%	ROI	-61.50%	52W High	-69.98%	Beta	2.06
Dividend TTM	-	Quick Ratio	7.10	Sales past 5Y	0.00%	Gross Margin	-	52W Low	8.48%	ATR (14)	0.45
Dividend Ex-Date	-	Current Ratio	7.10	EPS Y/Y TTM	5.80%	Oper. Margin	-	RSI (14)	38.97	Volatility	5.98% 8.15%
Employees	74	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	28.00
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-26.21%	Payout	-	Rel Volume	0.44	Prev Close	5.08
Sales Surprise	-	EPS Surprise	-5.08%	Sales Q/Q	-	Earnings	Nov 12 AMC	Avg Volume	1.14M	Price	4.99
SMA20	-11.58%	SMA50	-16.03%	SMA200	-51.70%	Trades		Volume	505,202	Change	-1.77%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-02-24	Initiated	Goldman	Buy	$24
Jan-30-24	Initiated	Citigroup	Buy	$20
Jul-21-23	Initiated	Oppenheimer	Outperform	$21
May-05-23	Initiated	CapitalOne	Overweight	$16
Feb-22-23	Initiated	Credit Suisse	Outperform	$12
Jul-06-22	Resumed	Canaccord Genuity	Buy	$16
Jun-09-22	Upgrade	H.C. Wainwright	Neutral → Buy	$12
Feb-28-22	Initiated	H.C. Wainwright	Neutral
Dec-07-21	Resumed	Cowen	Outperform
Dec-14-20	Initiated	JP Morgan	Overweight	$52
Dec-14-20	Initiated	Jefferies	Buy	$70
Dec-14-20	Initiated	Cowen	Outperform
Dec-14-20	Initiated	Canaccord Genuity	Buy	$60

Show Previous Ratings

Feb-19-25 04:30PM	Olema Oncology to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-18-25 07:00AM	Olema Oncology Appoints Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate Secretary (GlobeNewswire)
Feb-04-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.46%
Feb-03-25 04:30PM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-03-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.75% -6.62%
07:00AM	Loading…
Jan-02-25 07:00AM	Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-10-24 07:00AM	Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium (GlobeNewswire)
Dec-09-24 07:00AM	Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor (GlobeNewswire) -9.67%
Dec-03-24 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:17AM	Novartis and Olema expand alliance with $250m to boost breast cancer trials (Pharmaceutical Technology)
Dec-02-24 07:00AM	Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement (GlobeNewswire)
Nov-25-24 05:30PM	Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium (GlobeNewswire) +9.09%
Nov-24-24 07:27PM	Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors (PR Newswire)
Nov-12-24 04:01PM	Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -9.28%
Nov-06-24 07:01AM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
04:44PM	Loading…
Nov-04-24 04:44PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-23-24 07:00AM	Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024 (GlobeNewswire)
Oct-09-24 07:00AM	Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-02-24 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-04-24 04:49PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-21-24 07:00AM	Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-06-24 04:02PM	Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -9.90%
Aug-02-24 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -14.22%
Aug-01-24 08:50AM	Recent Price Trend in Olema Pharmaceuticals (OLMA) is Your Friend, Here's Why (Zacks)
Jul-02-24 04:29PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.55%
Jun-14-24 07:05PM	TruBridge, Evans Bancorp, and More Stocks See Action From Activist Investors (Barrons.com)
Jun-04-24 04:28PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +18.96%
May-28-24 07:03AM	Olema Oncology to Participate in Upcoming Investor Conferences in June (GlobeNewswire)
May-15-24 07:01AM	Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress (GlobeNewswire)
May-08-24 10:58PM	OLMA Stock Earnings: Olema Pharmaceuticals Misses EPS for Q1 2024 (InvestorPlace) -9.31%
04:02PM	Loading…
04:02PM	Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
07:02AM	Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress (GlobeNewswire)
May-03-24 12:15PM	Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032 (PR Newswire) +5.96%
May-02-24 04:37PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-01-24 07:02AM	Olema Oncology to Participate in Upcoming Investor Conferences in May (GlobeNewswire)
Apr-08-24 04:30PM	Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference (GlobeNewswire) +5.33%
Apr-05-24 12:16AM	Goldman Sachs Predicts Over 120% Rally for These 2 Strong Buy Stocks (TipRanks)
Apr-02-24 04:29PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-11-24 04:03PM	Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -6.62%
Mar-06-24 07:03AM	Olema Oncology Announces Publication of Data Highlighting Palazestrant's Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors (GlobeNewswire)
Mar-04-24 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.01%
Feb-06-24 07:01AM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-02-24 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-22-24 10:54AM	15 Small-Cap Stocks with High Potential (Insider Monkey)
Jan-08-24 08:12AM	Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate (GlobeNewswire)
Jan-02-24 04:01PM	Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-21-23 10:59AM	Hedge Fund and Insider Trading News: 3G Capital, Elliott Management, Harbor Capital, Three Arrows Capital, Nucor Corporation (NUE), Olema Pharmaceuticals, Inc. (OLMA), and More (Insider Monkey)
Dec-05-23 12:27PM	Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies (GlobeNewswire) -15.34%
Dec-04-23 04:29PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-01-23 09:30AM	Top Stocks for December 2023 (Investopedia)
Nov-28-23 05:10PM	Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS) (GlobeNewswire)
Nov-27-23 12:54PM	Olema Pharmaceuticals (OLMA) Skyrockets 471% YTD: Here's Why (Zacks) -5.79%
11:32AM	This Small Cap Is My Stock Pick, as the Market Shakes Its Hangover (TheStreet.com)
Nov-22-23 09:00AM	Olema Stock Has Soared 551% This Year. Its CEO Thinks It's Still Undervalued. (Investor's Business Daily)
Nov-07-23 04:02PM	Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) +10.43%
Nov-02-23 04:32PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.35% +5.40%
Nov-01-23 04:27PM	Olema Oncology to Participate in Upcoming Investor Conferences in November (GlobeNewswire) +12.42%
Oct-30-23 08:50AM	Olema Pharmaceuticals, Inc. (OLMA) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Oct-26-23 10:33AM	12 Best Performing NASDAQ Stocks in 2023 (Insider Monkey)
Oct-22-23 02:55AM	Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant (GlobeNewswire)
Oct-20-23 01:15PM	5 Best Performing Biotech Stocks in 2023 (Insider Monkey)
Oct-17-23 07:01AM	Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors (GlobeNewswire)
Oct-16-23 07:02AM	Olema Oncology Announces Phase 2 Monotherapy Clinical Results to be Presented at the 2023 ESMO Congress (GlobeNewswire) -16.55%
Oct-12-23 07:01AM	Olema Oncology KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity (GlobeNewswire)
Oct-11-23 09:55AM	Wall Street Analysts Believe Olema Pharmaceuticals, Inc. (OLMA) Could Rally 76.47%: Here's is How to Trade (Zacks) -5.18%
08:50AM	Here's Why Momentum in Olema Pharmaceuticals, Inc. (OLMA) Should Keep going (Zacks)
Oct-10-23 07:00AM	Olema Oncology Announces Expansion of Collaboration Agreement with Novartis (GlobeNewswire)
Oct-03-23 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-27-23 09:24PM	7 Strong Buy Biotech Stocks to Rejuvenate Your Portfolio (InvestorPlace)
Sep-25-23 09:55AM	Does Olema Pharmaceuticals, Inc. (OLMA) Have the Potential to Rally 80.29% as Wall Street Analysts Expect? (Zacks)
08:50AM	Here's What Could Help Olema Pharmaceuticals, Inc. (OLMA) Maintain Its Recent Price Strength (Zacks)
Sep-20-23 07:29AM	Olema Oncology Announces New Preclinical KAT6 Inhibitor Data to be Presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-15-23 01:09PM	BIOTECHNOLOGY VALUE FUND L P Acquires Stake in Olema Pharmaceuticals Inc (GuruFocus.com) +6.09%
Sep-14-23 11:02PM	Insider Buying: BIOTECHNOLOGY VALUE FUND L P Acquires 1,505,932 Shares of Olema Pharmaceuticals Inc (GuruFocus.com)
Sep-08-23 12:00PM	What Makes Olema Pharmaceuticals, Inc. (OLMA) a New Buy Stock (Zacks)
09:55AM	Wall Street Analysts Predict a 91.97% Upside in Olema Pharmaceuticals, Inc. (OLMA): Here's What You Should Know (Zacks)
Sep-07-23 04:02PM	The 7 Best Small-Cap Stocks to Buy Now: September 2023 (InvestorPlace)
Sep-06-23 04:30PM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire) -7.02%
Sep-05-23 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +19.51%
07:30AM	Olema Oncology Announces Combined Financing for Up to $180 Million (GlobeNewswire)
Aug-08-23 04:03PM	Olema Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) +12.05%
08:23AM	Here's Why We're Watching Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation (Simply Wall St.)
Aug-02-23 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.05%
Aug-01-23 08:00AM	Olema Oncology to Present at the Canaccord Genuity 43rd Annual Growth Conference (GlobeNewswire)
Jul-05-23 07:30AM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-14-23 01:00PM	3 Small-Cap Biotech Stocks With Positive Momentum (TheStreet.com)
Jun-02-23 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-30-23 04:30PM	Olema Oncology to Present at the 2023 Jefferies Healthcare Conference (GlobeNewswire)
May-19-23 06:29AM	Institutional investors own a significant stake of 42% in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) (Simply Wall St.)
May-11-23 08:43AM	Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1b/2 Study (GlobeNewswire)
May-09-23 04:01PM	Olema Oncology Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) +10.65% -8.67%
May-08-23 07:06AM	Olema Oncology Announces Upcoming Poster Presentation at the 2023 ESMO Breast Cancer Annual Congress (GlobeNewswire)
May-02-23 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +9.32%
Apr-13-23 04:30PM	Olema Oncology to Participate in Canaccord Genuity 2023 Horizons in Oncology Virtual Conference (GlobeNewswire) +7.67%
Apr-04-23 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.16%
Mar-09-23 04:00PM	Olema Oncology Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Strategic Update (GlobeNewswire)
Mar-02-23 05:00PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:05PM	Olema Oncology to Present at Oppenheimer 33rd Annual Healthcare Conference (GlobeNewswire)
Feb-21-23 04:30PM	Olema Oncology to Participate at Upcoming Investor Conferences (GlobeNewswire) -8.57% +9.62%
Feb-02-23 06:00PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.57%

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist, or CERAN, and a selective ER degrader, or SERD, which is believed to drive deeper, more durable responses than existing therapies. The company was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bain Capital Life Sciences Inv	10% Owner	Jan 08 '25	Buy	5.76	300,000	1,727,370	7,800,000	Jan 13 04:34 PM
Graham G. Walmsley	Director	Dec 17 '24	Sale	6.75	700,761	4,730,137	0	Dec 17 07:52 PM
Zojwalla Naseem	CHIEF MEDICAL OFFICER	Dec 16 '24	Option Exercise	4.87	14,000	68,180	129,509	Dec 17 07:29 PM
Logos Opportunities Fund I LP	Affiliate	Dec 13 '24	Proposed Sale	6.75	700,761	4,730,137		Dec 13 04:37 PM
Harmon Cyrus	Director	Dec 10 '24	Sale	9.37	8,256	77,359	772,277	Dec 11 07:56 PM
Harmon Cyrus	Director	Dec 11 '24	Sale	8.68	8,137	70,597	764,140	Dec 11 07:56 PM
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Dec 11 '24	Sale	8.68	13,614	118,116	598,333	Dec 11 07:56 PM
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Dec 10 '24	Sale	9.38	12,452	116,800	611,947	Dec 11 07:56 PM
Zojwalla Naseem	CHIEF MEDICAL OFFICER	Dec 11 '24	Sale	8.68	14,522	125,994	115,509	Dec 11 07:54 PM
Zojwalla Naseem	CHIEF MEDICAL OFFICER	Dec 10 '24	Sale	9.37	13,283	124,462	130,031	Dec 11 07:54 PM
Kovacs Shane William Charles	CH. OPERATING & FINANCIAL OFF.	Dec 11 '24	Sale	8.68	18,356	159,259	543,549	Dec 11 07:53 PM
Kovacs Shane William Charles	CH. OPERATING & FINANCIAL OFF.	Dec 10 '24	Sale	9.37	16,803	157,444	561,905	Dec 11 07:53 PM
Bohen Sean	PRESIDENT AND CEO	Dec 11 '24	Sale	8.68	57,174	496,052	241,662	Dec 11 07:52 PM
Bohen Sean	PRESIDENT AND CEO	Dec 10 '24	Sale	9.37	52,328	490,313	298,836	Dec 11 07:52 PM
Harmon Cyrus	Director	Dec 11 '24	Proposed Sale	8.68	8,137	70,635		Dec 11 05:19 PM
Kovacs Shane William Charles	Officer	Dec 11 '24	Proposed Sale	8.68	18,356	159,345		Dec 11 05:04 PM
Myles David C.	Officer	Dec 11 '24	Proposed Sale	8.68	13,614	118,180		Dec 11 04:52 PM
Zojwalla Naseem	Officer	Dec 11 '24	Proposed Sale	8.68	14,522	126,062		Dec 11 04:33 PM
Bohen Sean	Officer	Dec 11 '24	Proposed Sale	8.68	57,174	496,322		Dec 11 04:27 PM
Bohen Sean	Officer	Dec 10 '24	Proposed Sale	9.37	52,328	490,241		Dec 10 03:23 PM
Myles David C.	Officer	Dec 10 '24	Proposed Sale	9.38	12,452	116,748		Dec 10 02:48 PM
Harmon Cyrus	Director	Dec 10 '24	Proposed Sale	9.37	8,256	77,367		Dec 10 02:38 PM
Kovacs Shane William Charles	Officer	Dec 10 '24	Proposed Sale	9.37	16,803	157,426		Dec 10 02:21 PM
Zojwalla Naseem	Officer	Dec 10 '24	Proposed Sale	9.37	13,283	124,517		Dec 10 02:14 PM
Kovacs Shane William Charles	Ch. Operating & Financial Off.	Nov 15 '24	Option Exercise	7.02	25,000	175,500	510,458	Nov 18 06:00 AM
Paradigm Biocapital Advisors L	10% Owner	Aug 01 '24	Sale	14.91	2,400,000	35,796,000	783,118	Aug 05 04:30 PM
Harmon Cyrus	Director	Jul 29 '24	Sale	15.58	4,066	63,348	752,217	Jul 31 05:15 PM
Harmon Cyrus	Director	Jul 30 '24	Sale	15.55	934	14,524	751,283	Jul 31 05:15 PM
Harmon Cyrus	Director	Jul 30 '24	Proposed Sale	15.55	934	14,526		Jul 30 04:15 PM
Harmon Cyrus	Director	Jul 29 '24	Proposed Sale	15.58	4,066	63,352		Jul 29 04:23 PM
Harmon Cyrus	Director	Jul 11 '24	Sale	12.26	5,000	61,300	756,283	Jul 12 05:15 PM
Harmon Cyrus	Director	Jun 28 '24	Sale	10.77	20,000	215,400	761,283	Jul 02 05:30 PM
Graham G. Walmsley	Director	Jun 04 '24	Sale	14.85	1,175,000	17,448,750	700,761	Jun 06 05:01 PM
Harmon Cyrus	Director	May 31 '24	Sale	9.41	15,000	141,150	791,283	Jun 04 09:00 PM
Harmon Cyrus	Director	Jun 04 '24	Sale	12.33	5,000	61,650	781,283	Jun 04 09:00 PM
Harmon Cyrus	Director	Jun 03 '24	Sale	10.93	5,000	54,650	786,283	Jun 04 09:00 PM
Zojwalla Naseem	CHIEF MEDICAL OFFICER	May 24 '24	Option Exercise	4.87	9,460	46,070	89,824	May 28 05:00 PM
Harmon Cyrus	Director	May 06 '24	Sale	10.92	5,000	54,600	806,283	May 07 05:00 PM
Harmon Cyrus	Director	Apr 30 '24	Sale	9.51	15,000	142,650	811,283	May 02 05:09 PM
Harmon Cyrus	Director	Mar 28 '24	Sale	10.97	20,000	219,400	826,283	Mar 29 05:00 PM
Zojwalla Naseem	CHIEF MEDICAL OFFICER	Mar 18 '24	Option Exercise	4.87	13,700	66,719	80,364	Mar 20 05:30 PM
Harmon Cyrus	Director	Feb 29 '24	Sale	12.41	25,000	310,309	846,283	Mar 04 05:30 PM

Dollar change -0.06
Percentage change -2.11	%

KYTX Kyverna Therapeutics Inc daily Stock Chart

Peers: MRNA AMGN VRTX JNJ REGN GILD BMRN PFE BMY NVAX

| Held by: VTI IWM VXF IWO VTWO IBB SCHA IWN IWC SBIO

Index	RUT	P/E	-	EPS (ttm)	-3.07	Insider Own	55.89%	Shs Outstand	43.17M	Perf Week	-8.55%
Market Cap	120.02M	Forward P/E	-	EPS next Y	-3.70	Insider Trans	0.00%	Shs Float	19.04M	Perf Month	-15.50%
Income	-110.66M	PEG	-	EPS next Q	-0.84	Inst Own	32.74%	Short Float	14.63%	Perf Quarter	-36.89%
Sales	0.00M	P/S	-	EPS this Y	96.32%	Inst Trans	-1.56%	Short Ratio	7.00	Perf Half Y	-62.48%
Book/sh	7.01	P/B	0.40	EPS next Y	-12.14%	ROA	-	Short Interest	2.79M	Perf Year	-90.15%
Cash/sh	7.45	P/C	0.37	EPS next 5Y	66.11%	ROE	-	52W Range	2.64 - 30.60	Perf YTD	-25.67%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-35.94%	52W High	-90.92%	Beta	2.97
Dividend TTM	-	Quick Ratio	10.50	Sales past 5Y	-37.90%	Gross Margin	-	52W Low	5.10%	ATR (14)	0.27
Dividend Ex-Date	-	Current Ratio	10.50	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	36.43	Volatility	7.52% 9.23%
Employees	96	Debt/Eq	0.03	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.29	Target Price	20.67
Option/Short	Yes / Yes	LT Debt/Eq	0.02	EPS Q/Q	-122.75%	Payout	-	Rel Volume	0.86	Prev Close	2.84
Sales Surprise	-	EPS Surprise	1.76%	Sales Q/Q	-	Earnings	Nov 13 AMC	Avg Volume	397.87K	Price	2.78
SMA20	-10.68%	SMA50	-22.01%	SMA200	-59.58%	Trades		Volume	343,615	Change	-2.11%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-10-24	Initiated	UBS	Buy	$13
Oct-09-24	Initiated	Rodman & Renshaw	Buy	$16
Jul-03-24	Initiated	H.C. Wainwright	Neutral	$8
Mar-04-24	Initiated	Wells Fargo	Overweight	$44
Mar-04-24	Initiated	Morgan Stanley	Overweight	$40
Mar-04-24	Initiated	Leerink Partners	Outperform	$48
Mar-04-24	Initiated	JP Morgan	Overweight	$39

Feb-10-25 12:00PM	What Makes Kyverna Therapeutics, Inc. (KYTX) a New Buy Stock (Zacks)
Jan-21-25 04:05PM	Kyverna Therapeutics Appoints Naji Gehchan, MD, MBA, as Chief Medical and Development Officer (PR Newswire)
Jan-17-25 05:45AM	Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX (PR Newswire)
Jan-13-25 07:30AM	Kyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-08-25 08:00AM	Unnatural Products Appoints Abbas Kazimi and Mert Aktar to Board of Directors (GlobeNewswire)
05:45AM	Loading…
Jan-07-25 05:45AM	Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi and Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX (PR Newswire)
Jan-06-25 04:05PM	Kyverna Therapeutics to Present at the 43rd Annual J. P. Morgan Healthcare Conference (PR Newswire) -7.07%
Dec-27-24 05:45AM	Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi and Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX (PR Newswire)
Dec-19-24 12:16PM	Investors in Kyverna Therapeutics, Inc. Should Contact Levi and Korsinsky Before February 7, 2025 to Discuss Your Rights KYTX (GlobeNewswire)
Dec-13-24 04:05PM	Kyverna Therapeutics Strengthens Leadership Team to Accelerate Next Phase of Growth (PR Newswire)
Dec-09-24 06:38PM	Kyverna Therapeutics, Inc. Investors Who Have Lost Money Should Contact Block and Leviton to Find Out How They Might Recover Money Through A Recent Securities Lawsuit (GlobeNewswire) +6.81% -5.56%
Nov-14-24 10:01AM	Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024 (PR Newswire) -5.14%
Nov-13-24 04:14PM	Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results (PR Newswire)
Oct-21-24 08:00AM	Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors (PR Newswire) -7.80%
Oct-19-24 11:13AM	Kyverna Therapeutics (KYTX): Leading Nano Cap with Promising CAR T-Cell Therapy (Insider Monkey)
03:05PM	Loading…
Oct-10-24 03:05PM	JPMorgan Chase & Co's Strategic Acquisition in Kyverna Therapeutics Inc (GuruFocus.com)
Sep-18-24 08:00AM	Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024 (PR Newswire)
Sep-16-24 08:00AM	Kyverna Therapeutics Announces Leadership Update (PR Newswire)
06:58AM	Kyverna swaps CEOs, leaning on Kite veterans to lead next chapter (BioPharma Dive)
Aug-21-24 04:05PM	Kyverna Therapeutics to Participate in Upcoming September Investor Conferences (PR Newswire) +13.36% -5.36%
Aug-12-24 04:08PM	Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results (PR Newswire) +7.20%
04:05PM	Kyverna Therapeutics Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Progressive Myasthenia Gravis (PR Newswire)
Jul-16-24 11:33AM	Kyverna wins RMAT designation for stiff-person syndrome for cell therapy candidate (Pharmaceutical Technology) +11.71%
08:52AM	Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product (Zacks)
Jul-15-24 04:05PM	Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome (PR Newswire)
Jun-20-24 08:55AM	Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial (PR Newswire) +7.93%
Jun-17-24 04:05PM	First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS) (PR Newswire) -17.21% -5.70%
Jun-10-24 04:05PM	Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology (PR Newswire)
Jun-07-24 08:55AM	Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024 (PR Newswire)
May-14-24 10:54PM	KYTX Stock Earnings: Kyverna Therapeutics Misses EPS for Q1 2024 (InvestorPlace) +5.95%
04:05PM	Loading…
04:05PM	Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results (PR Newswire)
Apr-11-24 05:01PM	Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases (PR Newswire)
Mar-29-24 02:59PM	First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med (PR Newswire)
Mar-26-24 04:05PM	Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results (PR Newswire) +6.97%
Mar-14-24 07:00AM	Why That Hot Biotech IPO Could Be a Winner (The Wall Street Journal)
Mar-07-24 07:26PM	Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis (PR Newswire)
06:14PM	How Kyverna is positioned for success on autoimmune therapy: CEO (Yahoo Finance Video)
Feb-12-24 04:39PM	Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Feb-07-24 10:29PM	Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering (PR Newswire)

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company. It develops treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Walker Karen Marie	Chief Technology Officer	Jun 06 '24	Option Exercise	4.42	9,636	42,591	9,636	Jun 10 06:56 PM
Jones Ryan Alexander	Chief Financial Officer	May 28 '24	Option Exercise	0.73	18,016	13,152	43,950	May 29 04:33 PM

Open in Screener

ANNX

Annexon Inc

Feb 21 • 04:00PM ET

2.81

Dollar change -0.02
Percentage change -0.71	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX RARE CRSP NTLA EDIT ALLO BLUE FOLD MYO SGMO

| Held by: VTI IWM XBI VXF IWN VTWO IBB SCHA VHT DFAC

Index	RUT	P/E	-	EPS (ttm)	-1.04	Insider Own	13.12%	Shs Outstand	105.71M	Perf Week	-6.64%
Market Cap	299.53M	Forward P/E	-	EPS next Y	-1.08	Insider Trans	-0.43%	Shs Float	92.61M	Perf Month	-32.29%
Income	-117.50M	PEG	-	EPS next Q	-0.27	Inst Own	93.63%	Short Float	10.89%	Perf Quarter	-48.53%
Sales	0.00M	P/S	-	EPS this Y	46.05%	Inst Trans	2.64%	Short Ratio	7.11	Perf Half Y	-53.09%
Book/sh	3.14	P/B	0.90	EPS next Y	-13.42%	ROA	-40.34%	Short Interest	10.09M	Perf Year	-45.86%
Cash/sh	3.19	P/C	0.88	EPS next 5Y	17.54%	ROE	-48.12%	52W Range	2.63 - 8.40	Perf YTD	-45.22%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-29.69%	ROI	-32.75%	52W High	-66.55%	Beta	1.07
Dividend TTM	-	Quick Ratio	17.18	Sales past 5Y	0.00%	Gross Margin	-	52W Low	6.64%	ATR (14)	0.26
Dividend Ex-Date	-	Current Ratio	17.18	EPS Y/Y TTM	45.29%	Oper. Margin	-	RSI (14)	26.19	Volatility	8.86% 7.67%
Employees	71	Debt/Eq	0.09	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	15.17
Option/Short	Yes / Yes	LT Debt/Eq	0.08	EPS Q/Q	42.26%	Payout	-	Rel Volume	0.41	Prev Close	2.83
Sales Surprise	-	EPS Surprise	3.18%	Sales Q/Q	-	Earnings	Nov 14 BMO	Avg Volume	1.42M	Price	2.81
SMA20	-18.31%	SMA50	-34.43%	SMA200	-48.90%	Trades		Volume	578,088	Change	-0.71%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-01-24	Upgrade	JP Morgan	Neutral → Overweight	$11
Dec-21-23	Upgrade	BofA Securities	Neutral → Buy	$4 → $6
Oct-30-23	Initiated	Wells Fargo	Overweight	$11
May-26-23	Downgrade	BofA Securities	Buy → Neutral	$8 → $3
May-25-23	Downgrade	JP Morgan	Overweight → Neutral	$19 → $9
Sep-16-22	Initiated	Jefferies	Buy	$12
Sep-09-22	Initiated	BTIG Research	Buy	$15
Nov-30-21	Initiated	H.C. Wainwright	Buy	$40
Sep-23-21	Initiated	Cantor Fitzgerald	Overweight	$40
Jan-26-21	Initiated	Needham	Buy	$37
Aug-18-20	Initiated	JP Morgan	Overweight	$33
Aug-18-20	Initiated	Cowen	Outperform
Aug-18-20	Initiated	BofA Securities	Buy	$33

Show Previous Ratings

Feb-18-25 08:00AM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -12.05%
Feb-13-25 08:30AM	Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting (GlobeNewswire)
Jan-13-25 08:00AM	Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year (GlobeNewswire)
Jan-10-25 08:00AM	Annexon Expands Board of Directors with Appointment of Commercial Executive William BJ Jones (GlobeNewswire)
Jan-07-25 08:00AM	Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
04:05PM	Loading…
Dec-16-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +13.96%
07:30AM	Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barr Syndrome (GBS) (GlobeNewswire)
Dec-05-24 08:00AM	Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting (GlobeNewswire)
Nov-19-24 03:00AM	The Dodgers World Series run brought attention to a rare disease. Annexon is stepping up to the plate. (Pharma Voice)
Nov-15-24 04:59PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -10.78%
Nov-14-24 08:00AM	Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones (GlobeNewswire)
Nov-13-24 04:05PM	Annexon Biosciences to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-21-24 08:00PM	Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting (GlobeNewswire)
Oct-16-24 08:00AM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-15-24 08:00AM	Annexon to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting (GlobeNewswire)
08:00AM	Loading…
Sep-16-24 08:00AM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-09-24 08:00AM	Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in GA at the Retina Society 57th Annual Meeting and 24th Euretina Congress (GlobeNewswire) +8.17%
Sep-03-24 08:00AM	Annexon Expands Senior Leadership in Commercial, Medical Affairs and Health Economics to Advance Global Late-Stage Neuroinflammatory-Targeted Portfolio (GlobeNewswire) -5.09%
Aug-29-24 08:00AM	Annexon Biosciences to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-16-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-12-24 08:00AM	Annexon Reports Second Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones (GlobeNewswire)
Aug-05-24 08:00AM	Annexon Provides Update on ARCHER II Global Registrational Program in Geographic Atrophy (GlobeNewswire) -9.38%
Jul-16-24 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.02%
Jul-11-24 06:09PM	Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting (GlobeNewswire) +8.53% +11.15%
Jun-29-24 08:48PM	Are Analysts Bullish on Annexon, Inc. (ANNX) Right Now? (Insider Monkey)
Jun-28-24 09:40AM	Are Medical Stocks Lagging Annexon (ANNX) This Year? (Zacks)
Jun-27-24 09:55AM	Here's Why Annexon (ANNX) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Jun-25-24 05:00PM	Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barre Syndrome at the 2024 PNS Annual Meeting (GlobeNewswire)
05:00PM	Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barr Syndrome at the 2024 PNS Annual Meeting (GlobeNewswire)
Jun-24-24 06:35AM	7 Top Stocks Under $10: June 2024 Edition (InvestorPlace)
08:00AM	Loading…
Jun-18-24 08:00AM	Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barr Syndrome At 2024 PNS Annual Meeting (GlobeNewswire) -5.41%
Jun-17-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-07-24 09:40AM	Is Annexon (ANNX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-05-24 11:04PM	Annexon Announces Pricing of $125 Million Underwritten Public Offering (GlobeNewswire) +13.36% -13.25%
10:57AM	Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals (Zacks)
09:55AM	Wall Street Analysts Think Annexon (ANNX) Could Surge 133.72%: Read This Before Placing a Bet (Zacks)
04:45AM	Annexons ANX005 offers improvement in Phase III GBS trial (Clinical Trials Arena)
Jun-04-24 05:06PM	Annexon Announces Proposed Public Offering of Common Stock (GlobeNewswire) +30.79%
12:06PM	Mid-Cap Firm Annexon's Nerve Disorder Candidate Shows Promise In Pivotal Late-Stage Study (Benzinga)
08:46AM	Annexon shares leap as Guillain-Barr drug reduces disability in phase 3 (FierceBiotech.com)
07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:00AM	Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barre Syndrome (GlobeNewswire)
07:00AM	Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barr Syndrome (GlobeNewswire)
Jun-03-24 04:30PM	Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data (GlobeNewswire) -5.18%
May-20-24 09:35AM	Annexon (ANNX) Loses -5.04% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +8.08%
May-16-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-13-24 02:53PM	ANNX Stock Earnings: Annexon Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones (GlobeNewswire)
May-09-24 08:00AM	Annexon Biosciences to Present at the Bank of America Health Care Conference (GlobeNewswire)
May-07-24 12:30PM	Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting (GlobeNewswire)
May-01-24 10:15AM	Annexon (ANNX) to Report Q1 Earnings: What's in the Cards? (Zacks)
08:00AM	Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting (GlobeNewswire)
Apr-25-24 09:35AM	Down -43.02% in 4 Weeks, Here's Why You Should You Buy the Dip in Annexon (ANNX) (Zacks)
Apr-17-24 09:40AM	Are Medical Stocks Lagging Annexon (ANNX) This Year? (Zacks) -10.36%
Apr-16-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -10.89%
09:00AM	Turnstone Biologics Appoints William Waddill to its Board of Directors (GlobeNewswire)
Apr-14-24 12:52PM	10 Buy-Rated Stocks with Latest Insider Purchases (Insider Monkey)
Apr-10-24 06:15PM	Annexon, Inc. (ANNX) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
Apr-03-24 08:00AM	Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-01-24 12:00PM	What Makes Annexon (ANNX) a New Buy Stock (Zacks) -7.53%
09:55AM	Wall Street Analysts Believe Annexon (ANNX) Could Rally 101.12%: Here's is How to Trade (Zacks)
Mar-28-24 05:31AM	Annexon Inc (ANNX) Reports Year-End Financials, Aligns with Analyst Projections (GuruFocus.com) -8.19%
Mar-26-24 08:53PM	ANNX Stock Earnings: Annexon Beats EPS for Q4 2023 (InvestorPlace) +13.52%
04:05PM	Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones (GlobeNewswire)
Mar-18-24 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.98%
Mar-14-24 08:40AM	Why Annexon (ANNX) Might Surprise This Earnings Season (Zacks)
Mar-12-24 02:51PM	J.P. Morgan Predicts up to 140% Rally for These 2 Strong Buy Stocks (TipRanks)
Feb-27-24 08:00AM	Annexon Biosciences to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-21-24 08:00AM	Annexon to Host Virtual R&D Day on Guillain-Barr Syndrome, Focusing on its Serious Unmet Need and Annexon's Novel Therapeutic Approach (GlobeNewswire) -5.39%
Feb-20-24 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-13-24 01:10PM	Steven Cohen's Point72 Asset Management Acquires New Stake in Annexon Inc (GuruFocus.com) -7.73%
Jan-18-24 09:40AM	Is Annexon (ANNX) Stock Outpacing Its Medical Peers This Year? (Zacks) -5.87%
Jan-17-24 11:06AM	Annexon (ANNX) Stock Rallies 156% in 3 Months: Here's How (Zacks)
Jan-07-24 08:00PM	Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases (GlobeNewswire)
Dec-27-23 06:30AM	Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-20-23 05:27PM	Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock (GlobeNewswire) +29.51%
05:10PM	Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint (GlobeNewswire)
05:08PM	Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway (GlobeNewswire)
Dec-18-23 04:01PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-22-23 04:01PM	Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference (GlobeNewswire) +8.37%
Nov-14-23 07:20PM	Annexon Inc (ANNX) Reports Q3 2023 Financial Results and Clinical Progress (GuruFocus.com) +9.73%
Nov-13-23 06:30AM	Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results (GlobeNewswire) +6.35%
Nov-09-23 06:30AM	Annexon Biosciences to Participate in 2023 Jefferies London Healthcare Conference (GlobeNewswire)
Oct-24-23 06:30AM	Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic Atrophy (GlobeNewswire) +8.33%
Oct-18-23 04:01PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-10-23 06:30AM	Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal Program in Guillain-Barr Syndrome (GBS) (GlobeNewswire)
Sep-19-23 06:30AM	Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-18-23 04:01PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-08-23 09:35AM	Down -28.96% in 4 Weeks, Here's Why You Should You Buy the Dip in Annexon, Inc. (ANNX) (Zacks)
Aug-07-23 06:30AM	Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-02-23 04:01PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-30-23 12:00PM	Annexon Presents ARCHER Trial Results at ASRS 2023 Highlighting Potential of ANX007 as a Differentiated Treatment for Geographic Atrophy (GlobeNewswire)
Jul-27-23 06:30AM	Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer (GlobeNewswire) -6.82%
Jul-24-23 06:30AM	Annexon to Report ARCHER Phase 2 Trial Results in Geographic Atrophy at ASRS 2023 (GlobeNewswire)
Jun-14-23 08:36AM	Here's Why We're Watching Annexon's (NASDAQ:ANNX) Cash Burn Situation (Simply Wall St.) -5.48%
May-30-23 10:40AM	Annexon (ANNX) Stock Down More Than 50% Last Week: Here's Why (Zacks)
May-26-23 03:05AM	4 big analyst cuts: Snowflake downgraded twice on guidance miss (Investing.com) +35.71%
May-25-23 11:52AM	Why Shares of Annexon Are Plummeting Thursday (Motley Fool) -59.38%
10:12AM	Annexon's Eye Disease Drug Reports Mixed Trial Results, Will Focus On Planned Late-Stage Study (Benzinga)
May-24-23 04:01PM	Annexon Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function (GlobeNewswire) -7.84%

Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington's and alzheimer's disease, multiple sclerosis, glaucoma, parkinson's disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dananberg Jamie	CHIEF MEDICAL OFFICER	Feb 18 '25	Sale	2.96	5,521	16,342	33,479	Feb 20 04:54 PM
ARTIS DEAN RICHARD	EVP & CHIEF SCIENTIFIC OFFICER	Feb 18 '25	Sale	2.97	5,515	16,380	83,814	Feb 20 04:52 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Feb 18 '25	Sale	2.91	8,345	24,284	61,237	Feb 20 04:51 PM
Overdorf Michael	EVP & CHIEF BUSINESS OFFICER	Feb 18 '25	Sale	2.95	6,618	19,523	86,579	Feb 20 04:49 PM
Lew Jennifer	EVP & CHIEF FINANCIAL OFFICER	Feb 18 '25	Sale	2.92	6,912	20,183	77,770	Feb 20 04:48 PM
Love Douglas	PRESIDENT AND CEO	Feb 13 '25	Sale	2.95	5,021	14,812	351,554	Feb 18 04:30 PM
Lew Jennifer	EVP & CHIEF FINANCIAL OFFICER	Feb 13 '25	Sale	2.98	1,786	5,322	84,682	Feb 18 04:30 PM
Overdorf Michael	EVP & CHIEF BUSINESS OFFICER	Feb 13 '25	Sale	2.99	1,425	4,261	93,197	Feb 18 04:30 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Feb 13 '25	Sale	2.99	1,783	5,331	69,582	Feb 18 04:30 PM
Yednock Ted	Officer	Feb 18 '25	Proposed Sale	2.91	8,345	24,321		Feb 18 03:21 PM
Lew Jennifer	Officer	Feb 18 '25	Proposed Sale	2.92	8,338	24,319		Feb 18 03:15 PM
ARTIS DEAN RICHARD	Officer	Feb 18 '25	Proposed Sale	2.97	5,515	16,359		Feb 18 03:15 PM
Dananberg Jamie	Officer	Feb 18 '25	Proposed Sale	2.96	5,521	16,359		Feb 18 03:13 PM
Overdorf Michael	Officer	Feb 18 '25	Proposed Sale	2.95	6,618	19,514		Feb 18 03:11 PM
Yednock Ted	Officer	Feb 13 '25	Proposed Sale	2.98	1,783	5,316		Feb 13 03:18 PM
Love Douglas	Officer	Feb 13 '25	Proposed Sale	2.95	5,021	14,799		Feb 13 03:13 PM
Lew Jennifer	Officer	Feb 13 '25	Proposed Sale	2.98	1,786	5,314		Feb 13 03:12 PM
Overdorf Michael	Officer	Feb 13 '25	Proposed Sale	2.99	1,425	4,265		Feb 13 03:06 PM
Love Douglas	PRESIDENT AND CEO	Jan 06 '25	Option Exercise	1.41	37,994	53,556	356,575	Jan 08 05:58 PM
Carson William H.	Director	Dec 02 '24	Buy	5.33	3,200	17,056	25,600	Dec 04 06:12 PM
Love Douglas	PRESIDENT AND CEO	Oct 30 '24	Option Exercise	1.85	114,449	211,742	310,570	Nov 01 04:15 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Oct 15 '24	Option Exercise	1.85	5,408	10,005	76,773	Oct 17 05:09 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Oct 15 '24	Sale	7.41	5,408	40,073	71,365	Oct 17 05:09 PM
Yednock Ted	Officer	Oct 15 '24	Proposed Sale	7.41	5,408	40,073		Oct 15 02:03 PM
Carson William H.	Director	Oct 01 '24	Buy	5.97	3,200	19,104	22,400	Oct 02 04:15 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Sep 19 '24	Sale	7.10	4,500	31,950	0	Sep 20 04:30 PM
Yednock Ted	Officer	Sep 19 '24	Proposed Sale	7.10	4,500	31,950		Sep 19 12:32 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Sep 12 '24	Sale	6.16	5,500	33,880	4,500	Sep 16 04:30 PM
Yednock Ted	Officer	Sep 12 '24	Proposed Sale	6.16	5,500	33,880		Sep 12 10:24 AM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Sep 05 '24	Sale	5.64	5,500	31,020	10,000	Sep 06 04:30 PM
Yednock Ted	Officer	Sep 05 '24	Proposed Sale	5.64	5,500	31,020		Sep 05 10:15 AM
Carson William H.	Director	Sep 03 '24	Buy	5.48	3,200	17,536	19,200	Sep 04 04:34 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Aug 29 '24	Sale	5.95	5,500	32,725	15,500	Aug 30 06:00 PM
Yednock Ted	Officer	Aug 29 '24	Proposed Sale	5.95	5,500	32,725		Aug 29 02:08 PM
Carson William H.	Director	Aug 01 '24	Buy	6.24	3,200	19,968	16,000	Aug 05 07:53 PM
Overdorf Michael	EVP & CHIEF BUSINESS OFFICER	Jul 15 '24	Sale	6.02	784	4,720	94,622	Jul 17 04:49 PM
Lew Jennifer	EVP & CHIEF FINANCIAL OFFICER	Jul 15 '24	Sale	6.03	1,104	6,657	86,468	Jul 17 04:48 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Jul 15 '24	Sale	6.02	1,106	6,658	71,365	Jul 17 04:46 PM
Carson William H.	Director	Jul 01 '24	Buy	5.00	3,200	16,000	12,800	Jul 02 05:43 PM
Carson William H.	Director	Jun 03 '24	Buy	4.83	3,200	15,459	9,600	Jun 05 04:23 PM
Carson William H.	Director	May 01 '24	Buy	4.68	3,200	14,982	6,400	May 03 04:15 PM
Carson William H.	Director	Apr 08 '24	Buy	6.07	3,200	19,411	3,200	Apr 10 07:17 PM

SLDB

Solid Biosciences Inc

OLMA

Olema Pharmaceuticals Inc

KYTX

Kyverna Therapeutics Inc

ANNX

Annexon Inc

Upgrade your FINVIZ experience